The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The Dynamin-related protein 2b/drp2b gene in A. thaliana is not directly an immunity gene, but by helping move external material into the intracellular network is indirectly related, and some mutants increase susceptibility.
== History == Naltrexone was first synthesized in 1963 by Metossian at Endo Laboratories, a small pharmaceutical company in New York City. It was characterized by Blumberg, Dayton, and Wolf in 1965 and was found to be an orally active, long-acting, and very potent opioid antagonist. The drug showed advantages over earlier opioid antagonists such as cyclazocine, nalorphine, and naloxone, including its oral activity, a long duration of action allowing for once-daily administration, and a lack of dysphoria, and was selected for further development. It was patented by Endo Laboratories in 1967 under the developmental code name EN-1639A and Endo Laboratories was acquired by DuPont in 1969. Clinical trials for opioid dependence began in 1973, and a developmental collaboration of DuPont with the National Institute on Drug Abuse for this indication started the next year in 1974. The drug was approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan, and for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to Revia. A depot formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid dependence in 2010.
On December 1, 2024, Biden issued a "full and unconditional" pardon to his son Hunter that covered all federal offenses between that day and 2014, breaking his June 2024 pledge not to do so. In a statement announcing the pardon, Biden said he believed his son was "selectively, and unfairly, prosecuted". On his last full day in office, Biden pardoned five family members, including his brother James, and others targeted for retribution by his successor. They included former chairman of the Joint Chiefs of Staff Mark Milley, former National Institute of Allergy and Infectious Diseases director Anthony Fauci, and members and participants in the House Select Committee on the January 6 Attack. Biden said the pardons were preemptive, to protect the individuals against the incoming Trump administration's politically motivated vengeance, and should not be seen as an acknowledgment of wrongdoing.
In addition, Greek authorities seized a 7,000 square-metre plot of land on Paros, Greece in the Cyclades islands, which had been purchased jointly by Kaili and Giorgi. As the European Parliament convened for the first time following the scandal, on 13 December 2022, at its seat in Strasbourg, France, the offices of MEP Pietro Bartolo and Parliamentary official Mychelle Rieu were sealed by investigators. On 15 December, the European Public Prosecutor's Office (EPPO) requested that the European Parliament lift the parliamentary immunity of Eva Kaili and her fellow Greek MEP Maria Spyraki. The EPPO explained that the request was based on an investigative report from the European Anti-Fraud Office (OLAF), regarding raised "suspicion of fraud detrimental to the EU budget, in relation to the management of the parliamentary allowance." The request particularly pertained to funds paid to parliamentary assistants. On 2 January 2023, Belgian investigators submitted a request to the European Parliament to strip MEPs Marc Tarabella and Andrea Cozzolino of their parliamentary immunity. A hearing of the Parliament's Legal Affairs Committee was scheduled during the parliamentary sitting in Strasbourg on 16 January, allowing the accused MEPs to present their defence. The parties of both Tarabella and Cozzolino expressed their support for President Metsola's requests to assist the European Public Prosecutor's Office in the investigations and agreed to vote in favour of waiving their immunity. On 2 February, the European Parliament approved the request to lift their immunity.
Sources: en.wikipedia.org
== Structure type == In 1999, Meléndez et al. claimed that the structure of glycogen is optimal under a particular metabolic constraint model, where the structure was suggested to be "fractal" in nature. However, research by Besford et al. used small angle X-ray scattering experiments accompanied by branching theory models to show that glycogen is a randomly hyperbranched polymer nanoparticle. Glycogen is not fractal in nature. This has been subsequently verified by others who have performed Monte Carlo simulations of glycogen particle growth, and shown that the molecular density reaches a maximum near the centre of the nanoparticle structure, not at the periphery (contradicting a fractal structure that would have greater density at the periphery).
All branches connect at Jamaica station except the Port Washington Branch. Jamaica station also connects to Airtrain JFK for service to John F. Kennedy International Airport. Normally, the LIRR uses tracks 17 to 21 exclusively and shares tracks 13 to 16 with Amtrak and NJT. The LIRR uses tracks 11 and 12 on rare occasions.
== Research == Townsend's research has combined advanced proteomics and drug metabolism with biochemistry to identify molecular targets affected by oxidative and nitrosative stress. Her lab has focused on understanding the events leading to the endoplasmic reticulum (ER) stress response, specifically examining stress-induced impacts on proteins involved in protein folding. Her publication record includes an H-index of over 50, with more than 13,000 citations.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.